ClinicalTrials.gg
CompletedNCT02415439Updated Mar 10, 2017Results posted

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

A Phase 1 interventional study of VBP15 and Placebo in Healthy, sponsored by ReveraGen BioPharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-10.

Sponsored by ReveraGen BioPharma, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to examine the safety, tolerability, and PK of various increasing single and multiple doses of VBP15 in healthy adult subjects.

02

Conditions studied

  • Healthy

Keywords

  • Safety
  • tolerability
  • pharmacokinetics
  • adult
  • volunteers
03

In context

Lead sponsor

ReveraGen BioPharma, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For the Single Ascending Dose Study (SAD): Male subjects, ages 18 to 65 years, inclusive.
  • For the Multiple Ascending Dose Study (MAD): Male subjects or female subjects of nonchildbearing potential ages 18 to 65, inclusive.

Exclusion criteria

Exclusion Criteria:

  • For the MAD Study: Women of .
  • abnormal laboratory parameters
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    VBP15- 0.1 mg/kg SAD

    Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.

    Drug: VBP15

  • Experimental
    VBP15- 0.3 mg/kg SAD

    Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.

    Drug: VBP15

  • Experimental
    VBP15- 1.0 mg/kg SAD

    Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.

    Drug: VBP15

  • Experimental
    VBP15- 3.0 mg/kg SAD

    Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.

    Drug: VBP15

  • Experimental
    VBP15- 8.0 mg/kg Fasting SAD

    Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.

    Drug: VBP15

  • Experimental
    VBP15- 8.0 mg/kg Fed SAD

    Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.

    Drug: VBP15

  • Experimental
    VBP15- 20.0 mg/kg SAD

    Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.

    Drug: VBP15

  • Placebo comparator
    Placebo - SAD

    Subjects were orally administered a placebo under fasted conditions.

    Drug: Placebo

  • Experimental
    VBP15- 1.0 mg/kg 14 Day MAD

    Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.

    Drug: VBP15

  • Experimental
    VBP15- 3.0 mg/kg 14 Day MAD

    Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.

    Drug: VBP15

  • Experimental
    VBP15- 9.0 mg/kg 14 Day MAD

    Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.

    Drug: VBP15

  • Experimental
    VBP15- 20.0 mg/kg 14 Day MAD

    Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.

    Drug: VBP15

  • Placebo comparator
    Placebo MAD

    Subjects were orally administered placebo for 14 days under fasted conditions.

    Drug: Placebo

Interventions

  • DrugVBP15
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Effects After a Single Dose of VBP15

    Time frame: Participants will be followed for the duration of hospital stay of 4 days

  2. Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)

    Time frame: Participants will be followed for the duration of hospital stay of 4 days

  3. Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15

    Time frame: Participants will be followed for the duration of hospital stay of 4 days

  4. Number of Subjects With Adverse Effects After 14 Daily Doses of VBP15

    Time frame: Participants will be followed for the duration of hospital stay of 15 days

  5. Area Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose)

    Time frame: Participants will be followed for the duration of hospital stay of 15 days

  6. Peak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15

    Time frame: Participants will be followed for the duration of hospital stay of 15 days

07

Results

Posted Jan 5, 2017

Participant flow

In the single ascending dose (SAD) study, subjects were assigned to 1 of 7 dose groups and received a single oral dose of VBP15 or placebo. The multiple ascending dose (MAD) was initiated after a review of safety data from SAD groups. In the MAD study, subjects were randomized to 1 of 4 groups to receive VBP15 or placebo once daily for 14 days

Participant flow — Overall Study
MilestoneVBP15- 0.1 mg/kg SADVBP15- 0.3 mg/kg SADVBP15- 1.0 mg/kg SADVBP15- 3.0 mg/kg SADVBP15- 8.0 mg/kg Fasted SADVBP15- 8.0 mg/kg Fed SADVBP15- 20.0 mg/kg SADPlacebo SADVBP15- 1.0 mg/kg 14 Day MADVBP15- 3.0 mg/kg 14 Day MADVBP15- 9.0 mg/kg 14 Day MADVBP15- 20 mg/kg 14 Day MADPlacebo MAD
Started66666661266668
Completed66666661256668
Not completed0000000010000

Outcome measures

PrimaryNumber of Subjects With Adverse Effects After a Single Dose of VBP15
Time frame:
Participants will be followed for the duration of hospital stay of 4 days
Reported as:
Number · participants
Number of Subjects With Adverse Effects After a Single Dose of VBP15
participantsVBP15- 0.1 mg/kg SADVBP15- 0.3 mg/kg SADVBP15- 1.0 mg/kg SADVBP15- 3.0 mg/kg SADVBP15- 8.0 mg/kg Fasting SADVBP15- 8.0 mg/kg Fed SADVBP15- 20.0 mg/kg SADPlacebo SAD
Number of Subjects With Adverse Effects After a Single Dose of VBP1521110100
PrimaryArea Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)
Time frame:
Participants will be followed for the duration of hospital stay of 4 days
Reported as:
Mean · (hr*ng/mL)
Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)
(hr*ng/mL)VBP15- 0.1 mg/kg SADVBP15- 0.3 mg/kg SADVBP15- 1.0 mg/kg SADVBP15- 3.0 mg/kg SADVBP15- 8.0 mg/kg Fasted SADVBP15- 8.0 mg/kg Fed SADVBP15- 20.0 mg/kg SADPlacebo SAD
Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)42 ± 17161 ± 16486 ± 201578 ± 213997 ± 5510139 ± 258545 ± 300 ± 0
PrimaryPeak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15
Time frame:
Participants will be followed for the duration of hospital stay of 4 days
Reported as:
Mean · (ng/mL)
Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15
(ng/mL)VBP15- 0.1 mg/kg SADVBP15- 0.3 mg/kg SADVBP15- 1.0 mg/kg SADVBP15- 3.0 mg/kg SADVBP15- 8.0 mg/kg Fasting SADVBP15- 8.0 mg/kg Fed SADVBP15- 20.0 mg/kg SADPlacebo SAD
Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP1513 ± 1351 ± 17122 ± 33305 ± 24718 ± 431817 ± 311648 ± 170 ± 0
PrimaryNumber of Subjects With Adverse Effects After 14 Daily Doses of VBP15
Time frame:
Participants will be followed for the duration of hospital stay of 15 days
Reported as:
Number · participants
Number of Subjects With Adverse Effects After 14 Daily Doses of VBP15
participantsVBP15- 1.0 mg/kg 14 Days MADVBP15- 3.0 mg/kg 14 Days MADVBP15- 9.0 mg/kg 14 Days MADVBP15- 20.0 mg/kg 14 Days MADPlacebo MAD
Number of Subjects With Adverse Effects After 14 Daily Doses of VBP1520022
PrimaryArea Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose)
Time frame:
Participants will be followed for the duration of hospital stay of 15 days
Reported as:
Mean · (hr*ng/mL)
Area Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose)
(hr*ng/mL)VBP15- 1.0 mg/kg 14 Days MADVBP15- 3.0 mg/kg 14 Days MADVBP15- 9.0 mg/kg 14 Days MADVBP15- 20.0 mg/kg 14 Days MADPlacebo MAD
Area Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose)794 ± 221494 ± 194366 ± 209309 ± 390 ± 0
PrimaryPeak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15
Time frame:
Participants will be followed for the duration of hospital stay of 15 days
Reported as:
Mean · (ng/mL)
Peak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15
(ng/mL)VBP15- 1.0 mg/kg 14 Days MADVBP15- 3.0 mg/kg 14 Days MADVBP15- 9.0 mg/kg 14 Days MADVBP15- 20.0 mg/kg 14 Days MADPlacebo MAD
Peak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15153 ± 16281 ± 371082 ± 232416 ± 510 ± 0

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VBP15- 0.1 mg/kg SAD—0/6 (0%)2/6 (33.3%)
VBP15- 0.3 mg/kg SAD—0/6 (0%)1/6 (16.7%)
VBP15- 1.0 mg/kg SAD—0/6 (0%)1/6 (16.7%)
VBP15- 3.0 mg/kg SAD—0/6 (0%)1/6 (16.7%)
VBP15- 8.0 mg/kg Fasted SAD—0/6 (0%)0/6 (0%)
VBP15- 8.0 mg/kg Fed SAD—0/6 (0%)1/6 (16.7%)
VBP15- 20.0 mg/kg SAD—0/6 (0%)0/6 (0%)
Placebo SAD—0/12 (0%)0/12 (0%)
VBP15- 1.0 mg/kg 14 Days MAD—0/6 (0%)2/6 (33.3%)
VBP15- 3.0 mg/kg 14 Days MAD—0/6 (0%)0/6 (0%)
VBP15- 9.0 mg/kg 14 Days MAD—0/6 (0%)0/6 (0%)
VBP15- 20.0 mg/kg 14 Days MAD—0/6 (0%)2/6 (33.3%)
Placebo MAD—0/8 (0%)2/8 (25%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventVBP15- 0.1 mg/kg SADVBP15- 0.3 mg/kg SADVBP15- 1.0 mg/kg SADVBP15- 3.0 mg/kg SADVBP15- 8.0 mg/kg Fasted SADVBP15- 8.0 mg/kg Fed SADVBP15- 20.0 mg/kg SADPlacebo SADVBP15- 1.0 mg/kg 14 Days MADVBP15- 3.0 mg/kg 14 Days MADVBP15- 9.0 mg/kg 14 Days MADVBP15- 20.0 mg/kg 14 Days MADPlacebo MAD
HeadacheNervous system disorders1/60/61/60/60/60/60/60/121/60/60/61/60/8
Ear Pain, LeftEar and labyrinth disorders1/60/60/60/60/60/60/60/120/60/60/60/60/8
DizzinessNervous system disorders0/61/61/60/60/60/60/60/121/60/60/60/60/8
NauseaGastrointestinal disorders0/60/61/60/60/60/60/60/120/60/60/60/61/8
Non-cardiac chest painGeneral disorders0/60/60/61/60/60/60/60/120/60/60/60/60/8
Blood bilirubin, increasedInvestigations0/60/60/60/60/61/60/60/120/60/60/60/60/8
Pain extremity left elbowMusculoskeletal and connective tissue disorders0/60/60/60/60/60/60/60/121/60/60/60/60/8
SyncopeNervous system disorders0/60/60/60/60/60/60/60/121/60/60/60/60/8
Elevated liver enzyme: ALTInvestigations0/60/60/60/60/60/60/60/120/60/60/61/60/8
Elevated liver enzymesInvestigations0/60/60/60/60/60/60/60/120/60/60/60/61/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VBP15- 0.1 mg/kg SADVBP15- 0.3 mg/kg SADVBP15- 1.0 mg/kg SADVBP15- 3.0 mg/kg SADVBP15- 8.0 mg/kg Fasted SADVBP15- 8.0 mg/kg Fed SADVBP15- 20.0 mg/kg SADPlacebo SADVBP15- 1.0 mg/kg 14 Days MADVBP15 - 3.0 mg/kg 14 Days MADVBP15- 9.0 mg/kg 14 Days MADVBP15- 20.0 mg/kg 14 Days MADPlacebo MADTotal
<=18 years00000000000000
Between 18 and 65 years6666666126666886
>=65 years00000000000000
Sex: Female, Male
Sex: Female, Male(Participants)VBP15- 0.1 mg/kg SADVBP15- 0.3 mg/kg SADVBP15- 1.0 mg/kg SADVBP15- 3.0 mg/kg SADVBP15- 8.0 mg/kg Fasted SADVBP15- 8.0 mg/kg Fed SADVBP15- 20.0 mg/kg SADPlacebo SADVBP15- 1.0 mg/kg 14 Days MADVBP15 - 3.0 mg/kg 14 Days MADVBP15- 9.0 mg/kg 14 Days MADVBP15- 20.0 mg/kg 14 Days MADPlacebo MADTotal
Female00000000000000
Male6666666126666886
Region of Enrollment
Region of Enrollment(participants)VBP15- 0.1 mg/kg SADVBP15- 0.3 mg/kg SADVBP15- 1.0 mg/kg SADVBP15- 3.0 mg/kg SADVBP15- 8.0 mg/kg Fasted SADVBP15- 8.0 mg/kg Fed SADVBP15- 20.0 mg/kg SADPlacebo SADVBP15- 1.0 mg/kg 14 Days MADVBP15 - 3.0 mg/kg 14 Days MADVBP15- 9.0 mg/kg 14 Days MADVBP15- 20.0 mg/kg 14 Days MADPlacebo MADTotal
United States6666666126666886
08

Study locations

1 site
  • PRA Health Sciences
    Lenexa, Kansas 66219, United States
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Nov 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2015
First posted
Apr 14, 2015
Start
Jan 2015
Primary completionActual
Nov 2015
CompletionActual
May 2016
Results first posted
Jan 5, 2017
Last update
Mar 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02415439
Lead sponsor
ReveraGen BioPharma, Inc.
Responsible party
Sponsor
First posted
Apr 14, 2015
Start date
Jan 2015
Primary completion
Nov 2015
Completion
May 2016
Results posted
Jan 5, 2017
Last update
Mar 10, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion